Iranian journal of pharmaceutical research : IJPR · 2026
Anti-osteoporotic Effect of Solanum xanthocarpum Leaf Extract on Retinoic Acid-induced Osteoporosis in Rats via Alleviating Osteoclastic Activity.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wei Shuaishuai, Wang Jiayin, Liu Yi, Xu Chuang, Zheng Juncheng, Velu Periyannan, Vijayalakshmi Annamalai, Han Dapeng
Аннотация
BACKGROUND: Osteoporosis (OP) is a metabolic bone disorder that predominantly affects postmenopausal women. Solanum xanthocarpum (SX), a wild herb in the Solanaceae family, has traditionally been used to manage postmenopausal symptoms and articular cartilage injury.
OBJECTIVES: This study aimed to evaluate the anti-osteoporotic activity of Solanum xanthocarpum leaf extract (SXLE) in a rat model of retinoic acid (RA)-induced osteoporosis.
METHODS: Female Sprague-Dawley (SD) rats were randomly assigned to six experimental groups (n = 6 per group): group I, control; group II, RA alone (75 mg/kg body weight/day); group III, RA + alendronate (5 mg/kg body weight); group IV, RA + SXLE (25 mg/kg body weight); group V, RA + SXLE (50 mg/kg body weight); and group VI, RA + SXLE (100 mg/kg body weight). Bone mineral density (BMD), bone length, bone mineral content, serum estradiol levels, osteocalcin (OCN), alkaline phosphatase (ALP), and tartrate-resistant acid phosphatase (TRAP) activity were measured. The mRNA expression levels of TNF-α, IL-6, TP53 (tumor protein p53), NOX1 (NADPH oxidase 1), NOX2 (NADPH oxidase 2), SOD1 (superoxide dismutase 1), and SOD2 (superoxide dismutase 2) were evaluated by RT-qPCR.
RESULTS: SXLE treatment significantly increased body weight, bone mineral content, bone length, relative bone density, serum estradiol, osteocalcin, and BMD in a dose-dependent manner. Conversely, SXLE dose-dependently reduced ALP and TRAP activities and decreased the mRNA expression of TNF-α, IL-6, and TP53. SXLE improved tibial and femoral coefficients and lengths, increased trabecular relative bone density, and enhanced the cortical bone area ratio. The therapeutic effects of SXLE at 100 mg/kg body weight were comparable to those of alendronate (5 mg/kg body weight). Furthermore, SXLE downregulated the expression of NOX1 and NOX2 while upregulating the expression of SOD1 and SOD2.
CONCLUSIONS: SXLE enhances osteoblastic/osteogenic activity while suppressing osteoclastic activity, indicating significant anti-osteoporotic potential in rats with RA-induced osteoporosis. This is the first report to link SXLE to modulation of the NOX1/NOX2-SOD1/SOD2 oxidative stress pathway in bone, providing a potential molecular mechanism for its bone-protective effects. In addition, SXLE at 100 mg/kg demonstrated therapeutic efficacy comparable to that of alendronate, supporting its potential as a plant-based alternative to bisphosphonates for osteoporosis management.
OBJECTIVES: This study aimed to evaluate the anti-osteoporotic activity of Solanum xanthocarpum leaf extract (SXLE) in a rat model of retinoic acid (RA)-induced osteoporosis.
METHODS: Female Sprague-Dawley (SD) rats were randomly assigned to six experimental groups (n = 6 per group): group I, control; group II, RA alone (75 mg/kg body weight/day); group III, RA + alendronate (5 mg/kg body weight); group IV, RA + SXLE (25 mg/kg body weight); group V, RA + SXLE (50 mg/kg body weight); and group VI, RA + SXLE (100 mg/kg body weight). Bone mineral density (BMD), bone length, bone mineral content, serum estradiol levels, osteocalcin (OCN), alkaline phosphatase (ALP), and tartrate-resistant acid phosphatase (TRAP) activity were measured. The mRNA expression levels of TNF-α, IL-6, TP53 (tumor protein p53), NOX1 (NADPH oxidase 1), NOX2 (NADPH oxidase 2), SOD1 (superoxide dismutase 1), and SOD2 (superoxide dismutase 2) were evaluated by RT-qPCR.
RESULTS: SXLE treatment significantly increased body weight, bone mineral content, bone length, relative bone density, serum estradiol, osteocalcin, and BMD in a dose-dependent manner. Conversely, SXLE dose-dependently reduced ALP and TRAP activities and decreased the mRNA expression of TNF-α, IL-6, and TP53. SXLE improved tibial and femoral coefficients and lengths, increased trabecular relative bone density, and enhanced the cortical bone area ratio. The therapeutic effects of SXLE at 100 mg/kg body weight were comparable to those of alendronate (5 mg/kg body weight). Furthermore, SXLE downregulated the expression of NOX1 and NOX2 while upregulating the expression of SOD1 and SOD2.
CONCLUSIONS: SXLE enhances osteoblastic/osteogenic activity while suppressing osteoclastic activity, indicating significant anti-osteoporotic potential in rats with RA-induced osteoporosis. This is the first report to link SXLE to modulation of the NOX1/NOX2-SOD1/SOD2 oxidative stress pathway in bone, providing a potential molecular mechanism for its bone-protective effects. In addition, SXLE at 100 mg/kg demonstrated therapeutic efficacy comparable to that of alendronate, supporting its potential as a plant-based alternative to bisphosphonates for osteoporosis management.